Absci Corporation (ABSI)

$4.77

-0.2

(-4.02%)

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Absci Corporation

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 3.36M → 338.0K (in $), with an average decrease of 66.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -21.99M → -23.54M (in $), with an average decrease of 7.1% per quarter

Performance

  • $4.72
    $5.04
    $4.77
    downward going graph

    1.05%

    Downside

    Day's Volatility :6.35%

    Upside

    5.36%

    downward going graph
  • $1.11
    $6.72
    $4.77
    downward going graph

    76.73%

    Downside

    52 Weeks Volatility :83.48%

    Upside

    29.02%

    downward going graph

Returns

PeriodAbsci CorporationSector (Health Care)Index (Russel 2000)
3 Months
31.95%
-0.4%
0.0%
6 Months
278.57%
8.5%
0.0%
1 Year
180.59%
4.2%
-1.2%
3 Years
-77.91%
13.9%
-19.2%

Highlights

Market Capitalization
560.5M
Book Value
$1.89
Earnings Per Share (EPS)
-1.2
Wall Street Target Price
8.6
Profit Margin
0.0%
Operating Margin TTM
-7171.3%
Return On Assets TTM
-21.75%
Return On Equity TTM
-49.08%
Revenue TTM
5.7M
Revenue Per Share TTM
0.06
Quarterly Revenue Growth YOY
-78.3%
Gross Profit TTM
-39.8M
EBITDA
-79.7M
Diluted Eps TTM
-1.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.83
EPS Estimate Next Year
-0.74
EPS Estimate Current Quarter
-0.25
EPS Estimate Next Quarter
-0.2

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Absci Corporation(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
1
1

Analyst Forecast

What analysts predicted

Upside of 80.29%

Current $4.77
Target $8.60

Company Financials

FY19Y/Y Change
Revenue
2.1M
-
Net Income
-6.8M
-
Net Profit Margin
-330.15%
-
FY20Y/Y Change
Revenue
4.8M
↑ 132.04%
Net Income
-14.6M
↑ 114.22%
Net Profit Margin
-304.79%
↑ 25.36%
FY21Y/Y Change
Revenue
4.8M
↑ 0.04%
Net Income
-101.0M
↑ 592.98%
Net Profit Margin
-2.1K%
↓ 1806.46%
FY22Y/Y Change
Revenue
5.7M
↑ 20.18%
Net Income
-104.9M
↑ 3.91%
Net Profit Margin
-1.8K%
↑ 285.88%
FY23Y/Y Change
Revenue
5.7M
↓ 0.5%
Net Income
-110.6M
↑ 5.4%
Net Profit Margin
-1.9K%
↓ 108.28%
Q3 FY22Q/Q Change
Revenue
2.4M
↑ 136.43%
Net Income
-27.3M
↓ 4.95%
Net Profit Margin
-1.2K%
↑ 1711.63%
Q4 FY22Q/Q Change
Revenue
1.6M
↓ 34.28%
Net Income
-19.5M
↓ 28.57%
Net Profit Margin
-1.3K%
↓ 99.9%
Q1 FY23Q/Q Change
Revenue
1.3M
↓ 18.5%
Net Income
-23.4M
↑ 19.95%
Net Profit Margin
-1.8K%
↓ 589.88%
Q2 FY23Q/Q Change
Revenue
3.4M
↑ 165.33%
Net Income
-41.7M
↑ 78.43%
Net Profit Margin
-1.2K%
↑ 602.77%
Q3 FY23Q/Q Change
Revenue
744.0K
↓ 77.9%
Net Income
-22.0M
↓ 47.22%
Net Profit Margin
-3.0K%
↓ 1718.52%
Q4 FY23Q/Q Change
Revenue
338.0K
↓ 54.57%
Net Income
-23.5M
↑ 7.05%
Net Profit Margin
-7.0K%
↓ 4009.8%
FY19Y/Y Change
Total Assets
19.5M
-
Total Liabilities
60.6M
-
FY20Y/Y Change
Total Assets
88.6M
↑ 354.88%
Total Liabilities
178.0M
↑ 193.58%
FY21Y/Y Change
Total Assets
426.2M
↑ 381.2%
Total Liabilities
60.1M
↓ 66.24%
FY22Y/Y Change
Total Assets
321.0M
↓ 24.68%
Total Liabilities
46.6M
↓ 22.46%
FY23Y/Y Change
Total Assets
234.5M
↓ 26.96%
Total Liabilities
58.3M
↑ 25.13%
Q3 FY22Q/Q Change
Total Assets
339.4M
↓ 7.35%
Total Liabilities
46.4M
↓ 7.34%
Q4 FY22Q/Q Change
Total Assets
321.0M
↓ 5.42%
Total Liabilities
46.6M
↑ 0.32%
Q1 FY23Q/Q Change
Total Assets
295.8M
↓ 7.85%
Total Liabilities
41.8M
↓ 10.2%
Q2 FY23Q/Q Change
Total Assets
254.2M
↓ 14.08%
Total Liabilities
38.8M
↓ 7.38%
Q3 FY23Q/Q Change
Total Assets
236.3M
↓ 7.01%
Total Liabilities
39.9M
↑ 3.03%
Q4 FY23Q/Q Change
Total Assets
234.5M
↓ 0.79%
Total Liabilities
58.3M
↑ 46.02%
FY19Y/Y Change
Operating Cash Flow
-6.0M
-
Investing Cash Flow
-1.1M
-
Financing Cash Flow
12.7M
-
FY20Y/Y Change
Operating Cash Flow
-11.0M
↑ 81.86%
Investing Cash Flow
-2.2M
↑ 99.36%
Financing Cash Flow
71.0M
↑ 458.58%
FY21Y/Y Change
Operating Cash Flow
-60.6M
↑ 452.4%
Investing Cash Flow
-67.4M
↑ 3003.5%
Financing Cash Flow
336.2M
↑ 373.69%
FY22Y/Y Change
Operating Cash Flow
-81.3M
↑ 34.23%
Investing Cash Flow
-127.0M
↑ 88.46%
Financing Cash Flow
5.2M
↓ 98.44%
Q3 FY22Q/Q Change
Operating Cash Flow
-19.0M
↓ 15.66%
Investing Cash Flow
-78.7M
↑ 601.44%
Financing Cash Flow
-921.0K
↓ 115.82%
Q4 FY22Q/Q Change
Operating Cash Flow
-18.6M
↓ 2.49%
Investing Cash Flow
-30.2M
↓ 61.66%
Financing Cash Flow
1.4M
↓ 251.25%
Q1 FY23Q/Q Change
Operating Cash Flow
-20.1M
↑ 8.35%
Investing Cash Flow
-27.3M
↓ 9.54%
Financing Cash Flow
-1.1M
↓ 179.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.2M
↓ 4.4%
Investing Cash Flow
70.2M
↓ 356.96%
Financing Cash Flow
-1.2M
↑ 10.51%

Technicals Summary

Sell

Neutral

Buy

Absci Corporation is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Absci Corporation
Absci Corporation
-6.29%
278.57%
180.59%
-77.91%
-77.91%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Absci Corporation
Absci Corporation
NA
NA
NA
-0.83
-0.49
-0.22
NA
1.89
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Absci Corporation
Absci Corporation
Buy
$560.5M
-77.91%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • FMR Inc

    12.29%
  • Redmile Group, LLC

    7.12%
  • Vanguard Group Inc

    2.28%
  • Casdin Capital, LLC

    0.86%
  • BlackRock Inc

    0.75%
  • Junked Platinum Investment Management Ltd

    0.74%

Corporate Announcements

  • Absci Corporation Earnings

    Absci Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Absci Corporation
Employees
155
CEO
Mr. Sean McClain
Industry
Services

FAQs